Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Guaifenesin + pseudoephedrine hydrochloride is an oral combination drug used to relieve symptoms associated with upper respiratory tract conditions, such as the common cold, allergies (hay fever), and other breathing illnesses. Guaifenesin acts as an expectorant by thinning and loosening mucus in the airways, making it easier to clear congestion. Pseudoephedrine is a sympathomimetic decongestant that works by constricting blood vessels in the nasal passages, thereby reducing swelling and congestion. This combination does not treat infections but provides symptomatic relief from cough with mucus, runny or stuffy nose, sneezing, sinus pain, watery eyes, and chest congestion. It is available over-the-counter in various dosage forms including tablets (regular and extended-release), capsules, and liquids. The product is marketed under numerous brand names worldwide.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on guaifenesin + pseudoephedrine hydrochloride.